TCTC Holdings LLC Cuts Holdings in Abbott Laboratories $ABT

TCTC Holdings LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 6.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 92,595 shares of the healthcare product maker’s stock after selling 6,222 shares during the quarter. TCTC Holdings LLC’s holdings in Abbott Laboratories were worth $12,402,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Carr Financial Group Corp boosted its position in shares of Abbott Laboratories by 2.0% during the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after acquiring an additional 76 shares during the last quarter. Tortoise Investment Management LLC raised its stake in Abbott Laboratories by 10.7% during the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock valued at $108,000 after purchasing an additional 77 shares in the last quarter. Gemmer Asset Management LLC lifted its position in Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after purchasing an additional 78 shares during the last quarter. Bridgewater Advisors Inc. grew its stake in shares of Abbott Laboratories by 0.6% in the 2nd quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock worth $1,607,000 after buying an additional 79 shares in the last quarter. Finally, Global Financial Private Client LLC increased its holdings in shares of Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after buying an additional 79 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on ABT shares. Piper Sandler dropped their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Royal Bank Of Canada dropped their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Sanford C. Bernstein cut their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Leerink Partners lowered their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Finally, Oppenheimer cut their price objective on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Stock Up 1.0%

NYSE:ABT opened at $112.63 on Friday. The company has a market cap of $195.84 billion, a price-to-earnings ratio of 30.28, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The stock has a fifty day simple moving average of $119.48 and a 200-day simple moving average of $126.40.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the prior year, the business posted $1.34 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were paid a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.